milmedВоенная медицинаMilitary Medicine2074-5044Белорусский государственный медицинский университетmilmed-607Research ArticleСЛУЧАЙ ИЗ ПРАКТИКИCASE FROM PRACTICEОпыт коррекции антипсихотической терапии при необъяснимой тревоге у пациента с шизотипическим расстройством на основании полиморфизма генов GST-M1 и GST-Т1Experience of correction of antipsychotic therapy with unexplained anxiety in a patient with schizotypic disorder based on the polymorphism of GST-M1 and GST-T1 genesГоргунО. В.GorgunO. V.

Минск

ГемзаТ. Ф.GemzaT. F.

Минск

КононовичИ. В.KononovichI. V.

Минск

ГолоенкоИ. М.HolоenkoI. M.

Минск

ЛевданскийО. Д.HolоenkoI. M.

Минск

УО «Белорусский государственный медицинский университет» ; Городской клинический психиатрический диспансер ; Национальная академия наук Республики БеларусьBelarus20182210202603133137Copyright © Горгун О.В., Гемза Т.Ф., Кононович И.В., Голоенко И.М., Левданский О.Д., 20262026Горгун О.В., Гемза Т.Ф., Кононович И.В., Голоенко И.М., Левданский О.Д.Gorgun O.V., Gemza T.F., Kononovich I.V., Holоenko I.M., Holоenko I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://milmed.ejournal.by/jour/article/view/607

В статье рассматривается случай коррекции антипсихотической терапии при необъяснимой тревоге у пациента с шизотипическим расстройством на основании найденных мутаций в генах GST-M1 и GSTT1, которые свидетельствуют о нарушенной работе ферментов глутатион-S-трансфераз, что является причиной неспецифической эндогенной интоксикации активными метаболитами антипсихотиков и развития лекарственно индуцированной акатизии, которая может проявляться субъективными жалобами тревожного спектра.

The article deals with the case of correction of antipsychotic therapy with unexplained anxiety in a patient with schizotypal disorder based on found mutations in GST-M1 and GST-T1 genes, which indicate that glutathione-S-transferase enzymes have been impaired, which is the cause of non-specific endogenous intoxication by active metabolites of antipsychotics and the development of drug induced akathisia, which may be manifested by subjective complaints of anxiety spectrum.

шизотипическое расстройстволекарственно индуцированная акатизияэндогенная интоксикацияschizotypal disorderdrug induced akathisiaendogenous intoxicationReferencesJablensky A. (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry ClinNeurosci. Vol. 250, no. 6, pp. 274–285.Jablensky A. (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry ClinNeurosci. Vol. 250, no. 6, pp. 274–285.Gerlach J, Peacock L.(1995) New antipsychotics: the present status. In ClinPsychopharmacol. Vol. 10, pp. 39–48.Gerlach J, Peacock L.(1995) New antipsychotics: the present status. In ClinPsychopharmacol. Vol. 10, pp. 39–48.Steck H. (2006) Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments. Ann Med Psychol (Paris). Vol. 12, pp. 737–744.Steck H. (2006) Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments. Ann Med Psychol (Paris). Vol. 12, pp. 737–744.Poyurovsky M (2010). Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. Vol. 196, no. 2, pp. 89–91.Poyurovsky M (2010). Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. Vol. 196, no. 2, pp. 89–91.Plotnikova E. V. (2009) Lekarstvenno-inducirovannye dvigatel'nye rasstrojstva pri shizofrenii. Tavricheskij mediko-biologicheskij vestnik. T. 12, № 1 (45). S. 192–199.Plotnikova E. V. (2009) Lekarstvenno-inducirovannye dvigatel'nye rasstrojstva pri shizofrenii. Tavricheskij mediko-biologicheskij vestnik. T. 12, № 1 (45). S. 192–199.Sachdev P (2004) Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. Vol. 38, no. 6, pp. 445–9.Sachdev P (2004) Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. Vol. 38, no. 6, pp. 445–9.Duncan E. J., Adler L. A., Stephanides M. et al. (2000) Akathisia and exacerbation of psychopathology: a preliminary report. ClinNeuropharmacol. Vol. 23, pp. 169–173.Duncan E. J., Adler L. A., Stephanides M. et al. (2000) Akathisia and exacerbation of psychopathology: a preliminary report. ClinNeuropharmacol. Vol. 23, pp. 169–173.PeitlM. V., ProloščićJ., Blažević-ZelićS. (2011) Et al. Symptoms of agitated depression and/or akathisia. Psychiatr Danub. Vol. 23, no. 1, pp.108–110.PeitlM. V., ProloščićJ., Blažević-ZelićS. (2011) Et al. Symptoms of agitated depression and/or akathisia. Psychiatr Danub. Vol. 23, no. 1, pp.108–110.Reid A. M., McNamara J. P, Murphy T. K. (2015) Sideeffects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. J Psychiatr Res. Vol. 71, pp. 140–147.Reid A. M., McNamara J. P, Murphy T. K. (2015) Sideeffects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. J Psychiatr Res. Vol. 71, pp. 140–147.Lipinski J. F. Jr., Mallya G., Zimmerman P. et al.(1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. Vol. 50, no. 9, pp. 339–342.Lipinski J. F. Jr., Mallya G., Zimmerman P. et al.(1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. Vol. 50, no. 9, pp. 339–342.Temmingh H., Stein D. J. (2015) Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs. Vol. 29, no. 10, pp. 819–832.Temmingh H., Stein D. J. (2015) Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs. Vol. 29, no. 10, pp. 819–832.Kim JH, Byun HJ (2009). Non-motor cognitiveperceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol. Vol. 24, no. 2, pp. 129–134.Kim JH, Byun HJ (2009). Non-motor cognitiveperceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol. Vol. 24, no. 2, pp. 129–134.Kim JH, Kim SY, Byun HJ (2008). Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Parkinsonism Relat. Disord. Vol. 14, no. 3, pp. 239–242.Kim JH, Kim SY, Byun HJ (2008). Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Parkinsonism Relat. Disord. Vol. 14, no. 3, pp. 239–242.Lohr J. B., Eidt C. A., Abdulrazzaq Alfaraj A. et al. (2015) The clinical challenges of akathisia. CNS Spectr. 20 Suppl 1:1–14; quiz 15–16.Lohr J. B., Eidt C. A., Abdulrazzaq Alfaraj A. et al. (2015) The clinical challenges of akathisia. CNS Spectr. 20 Suppl 1:1–14; quiz 15–16.Berrios G. E. (1995) Lad Haskovec and akathisia: an introduction. Hist Psychiatry. 6 (22 Pt 2):243–251.Berrios G. E. (1995) Lad Haskovec and akathisia: an introduction. Hist Psychiatry. 6 (22 Pt 2):243–251.Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A. (2004) Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet.14:147-150.Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A. (2004) Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet.14:147-150.Белоусов Ю. Б., Кукес В. Г., Лепахин В. К., Петров В. И. (2009) Клиническая фармакология: национальное руководство. – М.: ГОЭТАР-Медиа. – С. 854–868.Белоусов Ю. Б., Кукес В. Г., Лепахин В. К., Петров В. И. (2009) Клиническая фармакология: национальное руководство. – М.: ГОЭТАР-Медиа. – С. 854–868.Nnadi CU, Malhotra AK. (2007) Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep. 9(4):313-318.Nnadi CU, Malhotra AK. (2007) Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep. 9(4):313-318.

The authors declare that there are no conflicts of interest present.